Performance of Dysmorphology‐Based Screening for Genetic Disorders in Pediatric Congenital Heart Disease Supports Wider Genetic Testing
Molecular Genetics & Genomic Medicine · 2024
DOI: 10.1002/mgg3.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Benjamin M Helm und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Heart Defects, Congenital, Genetic Testing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dysmorphology evaluation is important for congenital heart disease (CHD) assessment, but there are no prior investigations quantifying the screening performance compared to standardized genetics evaluations. We investigated this through systematic dysmorphology assessment in CHD patients with standardized genetic testing in primarily pediatric patients with CHD.
Methods
Dysmorphology evaluations preceding genetic testing results allowed us to test for associations between dysmorphic status and genetic diagnoses while adjusting for extracardiac anomalies (ECAs). We use a test‐negative case–control design on a pediatric inpatient CHD cohort for our study.
Results
Of 568 patients, nearly 96% of patients completed genetic testing, primarily chromosome microarray (CMA) ± exome sequencing‐based genetic testing (493/568, 86.8%). Overall, 115 patients (20.2%) were found to have genetic diagnoses, and dysmorphic patients had doubled risk of genetic diagnoses, after ECA adjustment (OR = 2.10, p = 0.0030). We found that 7.9% (14/178) of ECA−/nondysmorphic patients had genetic diagnoses, which increased to 13.5% (26/192) in the ECA−/dysmorphic patients. Nearly 43% of ECA+/dysmorphic patients had genetic diagnoses (63/147). The positive predictive value of dysmorphic status was only 26.3%, and the negative predictive value of nondysmorphic status was 88.7%.
Conclusions
Dysmorphology‐based prediction of genetic disorders is limited because of diagnoses found in apparently isolated CHD. Our findings represent one of the only assessments of phenotype‐based screening for genetic disorders in CHD and should inform clinical genetics evaluation practices for pediatric CHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Epidemiology, Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, Indiana, USA.
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Benjamin M Helm, Brett H Graham, Leah Wetherill
Zitieren
APA
Helm, B. M., Helvaty, L. R., Conboy, E., Geddes, G. C., Graham, B. H., Lah, M., Wetherill, L., Landis, B. J., & Ware, S. M. (2024). Performance of Dysmorphology‐Based Screening for Genetic Disorders in Pediatric Congenital Heart Disease Supports Wider Genetic Testing. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70040
Vancouver
Helm BM, Helvaty LR, Conboy E, Geddes GC, Graham BH, Lah M, et al. Performance of Dysmorphology‐Based Screening for Genetic Disorders in Pediatric Congenital Heart Disease Supports Wider Genetic Testing. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.70040
BibTeX
@article{Helm2024,
author = {Helm, Benjamin M and Helvaty, Lindsey R and Conboy, Erin and Geddes, Gabrielle C and Graham, Brett H and Lah, Melissa and Wetherill, Leah and Landis, Benjamin J and Ware, Stephanie M},
title = {Performance of Dysmorphology‐Based Screening for Genetic Disorders in Pediatric Congenital Heart Disease Supports Wider Genetic Testing},
journal = {Molecular Genetics & Genomic Medicine},
year = {2024},
doi = {10.1002/mgg3.70040}
}
EUVIMED